32.08

3.44% 1.075

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TEVA? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$31.00

Offen:

$31.63

24-Stunden-Volumen:

16.48M

Relative Volume:

1.56

Marktkapitalisierung:

$36.79B

Einnahmen:

$16.88B

Nettoeinkommen (Verlust:

$666.71M

KGV:

52.31

EPS:

0.6132

Netto-Cashflow:

$251.19M

1W Leistung:

+2.31%

1M Leistung:

+12.67%

6M Leistung:

+88.51%

1J Leistung:

+52.18%

1-Tages-Spanne:

$31.56

$32.91

1-Wochen-Bereich:

$30.47

$32.91

52-Wochen-Spanne:

$12.46

$32.91

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Firmenname

Teva Pharmaceutical Industries Ltd Adr

Sektor

Healthcare (1126)

Branche

Drug Manufacturers - Specialty & Generic (86)

Telefon

972 (3) 914-8213

Adresse

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Mitarbeiter

35,686

Twitter

@TevaUSA

Nächster Verdiensttermin

2025-01-29

Neueste SEC-Einreichungen

TEVA's Discussions on Twitter

Vergleichen Sie TEVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TEVA Teva Pharmaceutical Industries Ltd Adr	32.07	35.57B	16.88B	666.71M	251.19M	0.6132
ZTS Zoetis Inc	129.54	57.01B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	15.79	49.57B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.26	45.02B	14.26B	1.98B	2.47B	0.4327
UTHR United Therapeutics Corp	504.81	21.08B	3.08B	1.24B	1.07B	25.61

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-09	Eingeleitet	Barclays	Overweight
2025-12-05	Eingeleitet	Scotiabank	Sector Outperform
2025-06-06	Eingeleitet	Goldman	Buy
2025-05-28	Eingeleitet	Truist	Buy
2025-05-12	Hochstufung	JP Morgan	Neutral → Overweight
2024-07-10	Hochstufung	Argus	Hold → Buy
2024-03-08	Hochstufung	JP Morgan	Underweight → Neutral
2024-02-12	Hochstufung	Piper Sandler	Neutral → Overweight
2024-01-23	Hochstufung	Jefferies	Hold → Buy
2024-01-03	Hochstufung	Piper Sandler	Underweight → Neutral
2023-12-18	Eingeleitet	HSBC Securities	Buy
2023-11-27	Hochstufung	UBS	Neutral → Buy
2023-07-06	Hochstufung	UBS	Sell → Neutral
2023-05-25	Eingeleitet	Morgan Stanley	Equal-Weight
2023-05-18	Hochstufung	Evercore ISI	In-line → Outperform
2023-01-19	Herabstufung	Jefferies	Buy → Hold
2022-11-14	Herabstufung	JP Morgan	Neutral → Underweight
2022-11-04	Herabstufung	UBS	Neutral → Sell
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-08-05	Hochstufung	BofA Securities	Neutral → Buy
2022-06-14	Fortgesetzt	UBS	Neutral
2022-05-17	Hochstufung	BofA Securities	Underperform → Neutral
2022-05-04	Herabstufung	Piper Sandler	Neutral → Underweight
2022-04-05	Hochstufung	Barclays	Equal Weight → Overweight
2022-03-25	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-01-27	Herabstufung	Argus	Buy → Hold
2021-10-28	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-05-04	Herabstufung	UBS	Buy → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2020-11-25	Eingeleitet	Oppenheimer	Perform
2020-08-06	Hochstufung	Barclays	Underweight → Equal Weight
2020-07-27	Fortgesetzt	Goldman	Neutral
2020-06-01	Hochstufung	SunTrust	Hold → Buy
2020-04-24	Fortgesetzt	Citigroup	Neutral
2020-04-06	Hochstufung	UBS	Neutral → Buy
2020-02-24	Herabstufung	Edward Jones	Hold → Sell
2019-11-12	Hochstufung	JP Morgan	Underweight → Neutral
2019-10-17	Hochstufung	Gabelli & Co	Hold → Buy
2019-08-07	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-19	Eingeleitet	Wolfe Research	Peer Perform
2019-07-15	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-07-10	Fortgesetzt	Credit Suisse	Neutral
2019-07-05	Hochstufung	Argus	Hold → Buy
2019-06-11	Eingeleitet	Barclays	Underweight
2019-06-03	Hochstufung	Oppenheimer	Perform → Outperform
2019-05-30	Herabstufung	BofA/Merrill	Buy → Underperform
2019-05-28	Herabstufung	UBS	Buy → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2019-03-07	Fortgesetzt	UBS	Buy

Alle ansehen

Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten

Dec 30, 2025

The Truth About Teva Pharmaceutical (ADR): Is Wall Street Sleeping on This Comeback Play? - AD HOC NEWS

Dec 30, 2025

Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies - GlobeNewswire Inc.

Dec 30, 2025

What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? - Finviz

Dec 30, 2025

Dec 25, 2025

Has Teva’s Surging Share Price Outpaced Its Long Term Recovery Prospects? - Sahm

Dec 25, 2025

Dec 24, 2025

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - Sahm

Dec 24, 2025

Dec 22, 2025

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz

Dec 22, 2025

Dec 19, 2025

Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India

Dec 19, 2025

Dec 18, 2025

Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm

Dec 18, 2025

Dec 17, 2025

BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz

Dec 17, 2025

Dec 16, 2025

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 16, 2025

Dec 14, 2025

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - Finviz

Dec 14, 2025

Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? - Sahm

Dec 14, 2025

Dec 13, 2025

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 - Sahm

Dec 13, 2025

Dec 12, 2025

Teva Releases Q4 2025 Aide Memoire - Sahm

Dec 12, 2025

Dec 11, 2025

Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism - Sahm

Dec 11, 2025

Teva’s FDA Filing For Once-Monthly Schizophrenia Drug Might Change The Case For Investing In TEVA - Sahm

Dec 11, 2025

Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria

Dec 11, 2025

Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound - Sahm

Dec 04, 2025

Dec 01, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Dec 01, 2025

Nov 30, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz

Nov 30, 2025

Nov 28, 2025

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm

Nov 28, 2025

Nov 27, 2025

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm

Nov 27, 2025

Nov 26, 2025

Teva stock hits 52-week high at 26.38 USD - Investing.com

Nov 26, 2025

Nov 25, 2025

Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA) - Sahm

Nov 25, 2025

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm

Nov 25, 2025

Nov 19, 2025

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz

Nov 19, 2025

Nov 17, 2025